Andere Kunden interessierten sich auch für
![Clinical Assessment of Disease Severity in Patients with Psoriasis]( "Clinical Assessment of Disease Severity in Patients with Psoriasis")
Clinical Assessment of Disease Severity in Patients with Psoriasis32,99 €![Indicators of the severity of bronchial dilatation]( "Indicators of the severity of bronchial dilatation")
Indicators of the severity of bronchial dilatation40,99 €![THORACOABDOMINAL TRAUMA SEVERITY INDEX]( "THORACOABDOMINAL TRAUMA SEVERITY INDEX")
THORACOABDOMINAL TRAUMA SEVERITY INDEX27,99 €![Concordance study between ATS/ERS 2005 and 2021 recommendations]( "Concordance study between ATS/ERS 2005 and 2021 recommendations")
Concordance study between ATS/ERS 2005 and 2021 recommendations40,99 €![Frequency and severity of acute kidney injury in neonates with p-RIFLE]( "Frequency and severity of acute kidney injury in neonates with p-RIFLE")
Frequency and severity of acute kidney injury in neonates with p-RIFLE24,99 €![Study of Biomarkers Associated with Covid-19 Disease Progressions]( "Study of Biomarkers Associated with Covid-19 Disease Progressions")
Study of Biomarkers Associated with Covid-19 Disease Progressions29,99 €![Prostate Symptom Severity]( "Prostate Symptom Severity")
Prostate Symptom Severity27,99 €
The identification of biomarkers associated with psoriasis has the potential to predict susceptibility to psoriatic arthritis, provide evidence on natural history, therapeutic response and reveal pathogenic pathways that promote associated comorbidities. An increased inflammatory response has been documented in obesity, a condition that is associated with the occurrence and severity of psoriasis. Osteopontin (OPN), TNF and CXCL9 are increased in patients with psoriasis, although OPN has also been documented in the adipose tissue of obese patients without psoriasis. The prevalence of obesity is much higher in patients with psoriasis compared to the general population.